ACT Biotech Inc
ACT Biotech Inc is a San Francisco-based, privately held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs.[1][2] It was foudned in 2008.[3]
The Company's clinical stage pipeline includes :
- Telatinib, an oral kinase inhibitor for the first-line treatment of advanced gastric cancer. It has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA).[4] It has reported encouraging interim results from a phase II trial.[1]
- ACTB1003, an oral kinase inhibitor that targets cancer cells through multiple modes of action. It inhibits cancer cell growth by targeting the FGF receptor family, which are mutated in a number of human cancer types. ACTB1003 also directly induces apoptosis by targeting kinases downstream of the PI3K pathway, all at low nanomolar concentrations.
Other pipeline products include an oral Aurora A and B kinase inhibitor at the pre-IND stage, and an ABL tyrosine kinase inhibitor targeting the T315I mutant enzyme in pre-clinical development.
References
- 1 2 "ACT BIOTECH Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer". 11 Oct 2010.
- ↑ "ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare". 7 May 2008.
- ↑ Leuty, Ron (February 19, 2013). "ACT Biotech co-founder Ali Fattaey makes tracks to Curis". San Francisco Business Times. Retrieved October 24, 2016.
- ↑ "ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in". 2 June 2010.
External links
This article is issued from Wikipedia - version of the 10/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.